This study evaluated the effects of aldose reductase inhibition on diabetes-induced oxidative-
nitrosative stress and poly (ADP-ribose) polymerase (PARP) activation. In animal …

Aldose reductase inhibitors (ARIs) prevent peripheral nerve dysfunction and morphological
abnormalities in diabetic animal models. However, some experimental intervention studies …

Both increased aldose reductase (AR) activity and oxidative/nitrosative stress have been
implicated in the pathogenesis of diabetic nephropathy, but the relation between the two …

We examined the effects of long-term treatment with an aldose reductase inhibitor (ARI)
fidarestat on functional, morphological and metabolic changes in the peripheral nerve of 15 …

This study evaluated the role of poly (ADP-ribose) polymerase (PARP) in systemic oxidative
stress and 4-hydoxynonenal adduct accumulation in diabetic peripheral neuropathy. Control …

We investigated the effect of treatment with an aldose reductase inhibitor, insulin, or select
neurotrophic factors on the generation of oxidative damage in peripheral nerve. Rats were …

Aldose reductase inhibitors (ARIs) attenuate diabetic complications in several tissues,
including lens, retina, kidney, blood vessels, striated muscle and peripheral nerve. However …

Diabetes-associated oxidative stress is clearly manifest in peripheral nerve, dorsal root, and
sympathetic ganglia of the peripheral nervous system and endothelial cells and is implicated …

Aims/hypothesis Fidarestat, an aldose reductase inhibitor (ARI), has been reported to
improve clinical symptoms and nerve conduction deficits in human diabetic neuropathy. We …

Poly (ADP-ribose) polymerase (PARP) activation, an important factor in the pathogenesis of
diabetes complications, is considered a downstream effector of oxidative-nitrosative stress …